Calidi Biotherapeutics to Present RedTail Platform Progress at RedChip Conference
Event summary
- Calidi Biotherapeutics will present at RedChip’s virtual investor conference on April 16, 2026.
- The company expects to file an IND for CLD-401 by the end of 2026.
- Calidi is expanding the RedTail platform to include T-cell engagers in solid tumors.
- CLD-501, a RedTail virus expressing TROP2-targeting TCE and IL-15SA, is in development.
The big picture
Calidi Biotherapeutics is positioning itself as a leader in targeted genetic medicines with its RedTail platform, which aims to selectively target tumors and deliver therapeutic genetic payloads. The company’s focus on expanding the platform’s capabilities and pursuing strategic partnerships aligns with broader industry trends toward precision medicine and scalable healthcare solutions. The upcoming investor conference provides a platform for Calidi to showcase its progress and attract potential investors and partners.
What we're watching
- IND Filing Timeline
- Whether Calidi can meet its target of filing an IND for CLD-401 by the end of 2026.
- Platform Expansion
- The pace at which Calidi can expand the RedTail platform to include new payloads and indications.
- Strategic Partnerships
- How potential partnerships will accelerate the clinical development of the RedTail platform.
Related topics